| The first coronavirus vaccine that aims to protect people with just a single shot has entered the final stages of testing in the United States, in an international trial that will recruit up to 60,000 participants. Paul Stoffels, chief scientific officer of J&J, said there may be enough data to have results by the end of the year on whether the vaccine is safe and effective, adding that the company plans to manufacture 1 billion doses next year. | 
No comments:
Post a Comment